Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden.
Brandefors L et al. Acta Oncol. 2015 Nov 11:1-8. [Epub ahead of print]
Oral Ixazomib Maintenance Therapy in Multiple Myeloma. Offidani M et al. Expert Rev Anticancer Ther. 2015 Nov 20. [Epub ahead of print]. Effective use of panobinostat in combination with other active agents in myeloma in a novel 5-drug combination: Case Report and Interesting Observations. Rajan AM et al. Am J Hematol. 2015 Nov 17. doi: 10.1002/ajh.24244. [Epub ahead of print]. Efficacy and safety of…
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Weinhold N et al. Haematologica. 2015 Nov 26. pii: haematol.2015.136929. [Epub ahead of print]. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Dykstra KM et al. Oncotarget. 2015 Nov 22. doi: 10.18632/oncotarget.6365. [Epub ahead of print]. The role of circulating miRNAs in multiple myeloma.…
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Santo L et al. Semin Oncol. 2015 Dec;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024. Epub 2015 Sep 24. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. Guerard EJ et al. Clin Geriatr Med. 2016 Feb;32(1):191-205. doi: 10.1016/j.cger.2015.08.012. Epub 2015 Oct 9. Multiple myeloma and physical activity: a scoping review. Smith L et al. BMJ Open. 2015 Nov 27;5(11):e009576.…
A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. Liu A et al. Acta Haematol. 2015 Nov 21;135(3):140-145. [Epub ahead of print]. CD4(+)CD25(+) cells in multiple myeloma related renal impairment. Huang H et al. Sci Rep. 2015 Nov 13;5:16565. doi: 10.1038/srep16565. Complications after surgery for metastatic humeral lesions. Janssen SJ et al. J Shoulder Elbow Surg. 2015 Nov 4. pii: S1058-2746(15)00446-2. doi: 10.1016/j.jse.2015.08.009. [Epub ahead…
Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. Aznab M et al. Asia Pac J Clin Oncol. 2015 Nov 4. doi: 10.1111/ajco.12418. [Epub ahead of print]. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Hungria VT et al. Ann Hematol. 2015 Oct 30. [Epub ahead…
This study describes the results of the first metabolomic analysis of MGUS, myeloma and normal bone marrow and peripheral blood samples, demonstrating its potential to improve the understanding of the development of MGUS and progression to myeloma.
This study shows benefits from zoledronic acid monotherapy in myeloma patients with asymptomatic biochemical relapse and suggests that it should be considered as a new standard of care for this group.
Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Siontis B et al. Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87. 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Zamagni E et al. Leukemia. 2015 Oct 22. doi: 10.1038/leu.2015.291. [Epub ahead of print]. MMSA-1 expression pattern in multiple myeloma and…
TCL1 expression patterns in Waldenström macroglobulinemia. Lemal R et al. Mod Pathol. 2015 Oct 23. doi: 10.1038/modpathol.2015.122. [Epub ahead of print]. Cast nephropathy: an extremely rare renal presentation of Waldenström’s macroglobulinaemia. Santos T et al. BMJ Case Rep. 2015 Oct 7;2015. pii: bcr2015211210. doi: 10.1136/bcr-2015-211210. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia. Alfaraj WA et…